Purisys

Purisys is a global leader in the custom synthesis of active pharmaceutical ingredients, offering support to pharma and biotech companies with APIs, reference standards, controlled substances, cannabinoids, psychedelics, and cGMP clinical and niche commercial CDMO services. Established in 2019 as a spin-off from Noramco, Purisys traces its manufacturing roots back to 1979 as part of Johnson & Johnson. The company is renowned for producing over 50 major and minor cannabinoids, along with degradants, metabolites, and analytical standards, thereby addressing the evolving needs of the industry. Notably, they hold DEA licenses for several psychedelic basic classes and have successfully manufactured GMP psilocybin and Psilocin to support customers’ R&D programs. Purisys stands out for providing comprehensive development, analytical, and manufacturing services from preclinical to commercial APIs for pharmaceutical and biotech clients. Their capabilities extend to difficult-to-manufacture APIs, including controlled substances, injectable-grade APIs, HPAPIs, and environmentally sensitive APIs. The company's stock of 250+ reference standards with structural elucidation and comprehensive analytical data is distributed to 30+ countries across 6 continents. Their capabilities also include excipient compatibility, formulation, solid state, cGMP manufacturing, HPAPI, and labile molecule development, and method development. Overall, Purisys offers a wide range of services and products that cater to the needs of the pharmaceutical and biotech industries, positioning itself as a key player in the global pharmaceutical and biotech landscape.